Is Anavex Life Sciences Corp. (AVXL) a Buy, Sell, or Hold?
Anavex Life Sciences Corp.
NASDAQ:AVXL
$2.43 USD
$0.0 (0.0%)
- Volume
- 68.43K
- Average Volume
- 1.19M
- Market Capitalization
- $225.19M
- P/E Ratio
- -5.24
- Dividend Yield
- 0.00%
- Price Target
- $11.00
- Year High
- $13.99
- Year Low
- $2.30
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $20.87
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Christopher U. Missling |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | AVXL |
| CUSIP | 032797300 |
| CIK | 0001314052 |
| Web | https://www.anavex.com |
| Phone | 844 689 3939 |
| Currency | USD |
| Employees | 34 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 20.87 |
| Quick Ratio | 20.87 |
| Cash Ratio | 20.68 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -0.38 |
| Price / Cash Flow | -6.61 |
| Price / Book | 1.71 |
Price Target and Rating
| Average Stock Price Forecast | $11.00 |
| High Stock Price Forecast | $11.00 |
| Low Stock Price Forecast | $11.00 |
| Forecast Upside/Downside | -77.91% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 13 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.54 |
| Trailing P/E Ratio | -5.24 |
| PEG Ratio | -0.32 |
| P/E Growth | -0.32 |
| Net Income | $-46.38M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -38.76% |
| Return on Assets | -30.04% |
Financials Score
| AltmanZ Score | 17.91 |
| Piotroski Score | 2.00 |
| Working Capital | 126.62M |
| Total Assets | 132.99M |
| Ebit | -38.87M |
| Market Cap | 231.68M |
| Total Liabilities | 6.37M |
Poll Results
About Anavex Life Sciences Corp. (NASDAQ:AVXL) Stock
Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome. This same drug is also in Phase II trials for Parkinson's disease and is being explored in preclinical studies for a wider range of disorders, including epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Another significant drug candidate, ANAVEX 3-71, has progressed to Phase I clinical trials for frontotemporal dementia and other forms of dementia, with additional pr ... eclinical investigation underway for neurodegenerative illnesses like Alzheimer's and Parkinson's. The company's earlier-stage portfolio includes ANAVEX 1-41, a sigma-1 receptor agonist targeting depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand with potential applications in neuropathic and visceral pain; and ANAVEX 1037, aimed at treating prostate and pancreatic cancers. Anavex Life Sciences Corp. was founded in 2004 and maintains its headquarters in New York, New York.
Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification
2026-05-22 08:00:00
NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) disorders, today announced it received an expected delinquency notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on May 20, 2026. The Notice indicates that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Nasdaq Listing Rule”) as a result of the Company's inability to timely file its Form 10-Q for the quarterly period ended March 31, 2026.
2026-05-06 07:00:00
NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that its Board of Directors has appointed the Company's former Senior Vice President of Clinical Development and current Senior Advisor, Terrie Kellmeyer, PhD, as Interim Chief Executive Officer. These appointments follow the departure of President and Chief Executive Officer Christopher Missling, PhD, MS, MBA, from the Company on April 30, 2026, and a request for his resignation from the Board of Directors.
Frequently Asked Questions
-
What is the current Anavex Life Sciences Corp. (AVXL) stock price?
-
Anavex Life Sciences Corp.(NASDAQ:AVXL) stock price is $2.43 in the last trading session. During the trading session, AVXL stock reached the peak price of $13.99 while $2.2995 was the lowest point it dropped to. The percentage change in AVXL stock occurred in the recent session was 0.0% while the dollar amount for the price change in AVXL stock was $0.0.
-
AVXL's industry and sector of operation?
-
The NASDAQ listed AVXL is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of AVXL?
-
Sandra Boenisch | Principal Financial Officer & Treasurer
Clint Tomlinson | Vice President of Corporate
Terrie Kellmeyer | Interim Chief Executive Officer
Adebayo Laniyonu | Senior Vice President of Nonclinical Development
Juan Carlos Lopez-Talavera | Senior Vice President & Head of Research and Development -
How many employees does AVXL have?
-
Number of AVXL employees currently stands at 34. AVXL operates from 51 West 52nd Street, New York City, NY 10019, US.
-
Link for AVXL official website?
-
Official Website of AVXL is: https://www.anavex.com
-
How do I contact AVXL?
-
AVXL could be contacted at phone #844 689 3939 and can also be accessed through its website. AVXL operates from 51 West 52nd Street, New York City, NY 10019, US.
-
How many shares of AVXL are traded daily?
-
The average number of AVXL shares traded daily for last 3 months was 1.19M.
-
What is the market cap of AVXL currently?
-
The market value of AVXL currently stands at $225.19M with its latest stock price at $2.43